long intergenic non-protein coding RNA 1366Genealiases: []
Q-omics provides the consensus-scored LINC01366 profile across patient tissues and cancer cell-line models. LINC01366 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, LINC01366 is differentially expressed in 11, with the highest sampling consensus in LUSC. Additionally, LINC01366 RNA expression shows 14,862 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight STAD, LUSC, and UVM as cancer lineages where LINC01366 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01366 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01366 survival associations across molecular data types. LINC01366 RNA expression shows survival associations in the most cancer types (26). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01366 RNA expression–survival associations across cancer types. High LINC01366 expression shows unfavorable associations in STAD, KICH, LIHC, KIRP and LGG, but favorable associations in ACC. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify STAD as the clearest survival context for LINC01366 RNA expression.
This table summarizes LINC01366 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01366. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01366 shows lower tumor expression in LUSC, LUAD, BRCA and UCEC and higher tumor expression in THCA and KIRC. The LUSC box plot shows higher LINC01366 RNA expression in normal versus tumor tissue (log2 FC = −1.009, t-test p < 0.001).
This table shows molecular features associated with LINC01366 in patient tissues and cancer cell lines. In patient samples, LINC01366 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, LINC01366 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE.
